Catalyst Pharmaceuticals, Inc. Free Cash Flow 2002–2025
Catalyst Pharmaceuticals, Inc. reported $208.61M of free cash flow for fiscal 2025. That was 12.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +363.3%.
| Fiscal year | Free Cash Flow | Change (YoY) |
|---|---|---|
| FY 2025 | $208.61M | -12.8% |
| FY 2024 | $239.25M | +66.9% |
| FY 2023 | $143.37M | +23.6% |
| FY 2022 | $116.02M | +95.5% |
| FY 2021 | $59.35M | +31.8% |
| FY 2020 | $45.02M | +30.2% |
| FY 2019 | $34.59M | +231.8% |
| FY 2018 | $-26.24M | -90.9% |
| FY 2017 | $-13.74M | +23.9% |
| FY 2016 | $-18.06M | -0.1% |
| FY 2015 | $-18.04M | -38.8% |
| FY 2014 | $-13.00M | -31.5% |
| FY 2013 | $-9.89M | -90.4% |
| FY 2012 | $-5.19M | -4.1% |
| FY 2011 | $-4.99M | -32.7% |
| FY 2010 | $-3.76M | +51.1% |
| FY 2009 | $-7.69M | — |
| FY 2008 | $0 | — |
| FY 2007 | $0 | — |
| FY 2006 | $0 | — |
| FY 2005 | $0 | — |
| FY 2004 | $0 | — |
| FY 2003 | $0 | — |
| FY 2002 | $0 | — |
Source: Catalyst Pharmaceuticals, Inc. SEC filings — cash flow statement (10-K). Computed deterministically; refreshed nightly (last updated August 2, 2026). Open CPRX 10-K filings at SEC EDGAR · Methodology · Download CSV.
How to read this history
Catalyst Pharmaceuticals, Inc. reported $208.61M of free cash flow for fiscal 2025. That was 12.8% lower than fiscal 2024. Compared with fiscal 2020, the change was +363.3%. Values remain missing when the cached filing does not disclose a comparable line item; they are never estimated. Stock splits, reorganizations and fiscal-calendar changes can reduce comparability.
Prepared and reviewed by the stockportfolio.pro research desk. Corrections: support@stockportfolio.pro.
See the full picture for Catalyst Pharmaceuticals, Inc.
Complete income statement, balance sheet and cash flow with trend on every row, 48 quarters, ratios, health checks, and Ask — the SEC-grounded research assistant.
Open the interactive view — freeCatalyst Pharmaceuticals, Inc. — frequently asked questions
What is Catalyst Pharmaceuticals, Inc.'s free cash flow?
Catalyst Pharmaceuticals, Inc. (CPRX) reported free cash flow of $208.61M for fiscal year 2025, per its SEC filings.
Where does this data come from?
Figures are computed from Catalyst Pharmaceuticals, Inc.'s official SEC filings (cash flow statement (10-K)), refreshed nightly. Not investment advice.